Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV TXA in Gender Affirming Mastectomy
NCT05794321Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Sep 2023
- Primary completion
- May 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tranexamic acid in postoperative hematoma and Seroma (2 arms), sponsored by University of California, San Francisco. Primary endpoints: Number of Participants with Clinically Significant Hematomas at 3 months, Number of Participants with Clinically Significant Seromas at 3 months and 2 more. Started Sep 2023; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
postoperative hematomaSeroma
Beyond the preview
Go deeper on NCT05794321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794321.